A Covid-19 vaccine from GlaxoSmithKline Plc and Canada’s Medicago Inc. demonstrated 71% efficacy against multiple variants of the disease in a positive outcome for the pandemic latecomers.
A federal committee last week “strongly recommending” giving third doses to people 50+ but Quebec has decided it’s not necessary for the moment” for those 50 to 59, Dubé says.